New interim fda director's previous paper on mouse models blow; again showing the failure percent with cancer during the phases, what I believe is little reaction so far with cancer, until phase 2 data. It helps our odds greatly though that maraviroc already has success in human trials and leronlimab worked slightly better in mouse models than maraviroc. Bring on the ctc numbers! Since most failures happen in phase 2 with cancer, once it is clear phase 2 will be successful, the odds of approval increase 4 fold. The market should react accordingly, and they should get some strong partnership interest.

He also has some research on tnbc, I''m sure he is aware of Prestell's work.
https://www.ncbi.nlm.nih.gov/pubmed/22500798



https://www.nature.com/articles/nrd2110.pdf